X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Insulin Lispro,Pramlintide
Therapeutic Area: Endocrinology Product Name: BC LisPram
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
Details:
Data from all cohorts from its Phase 1 Single Ascending Dose clinical trial evaluating AZP-3601, a parathyroid hormone (PTH) analog specifically designed for the treatment of hypoparathyroidism will be presented.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021
Details:
AZP-3601 is a therapeutic peptide designed to target a specific configuration of the parathyroid hormone (PTH) receptor in order to safely produce sustained levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
